loading page

Influenza vaccine effectiveness in Europe: Results from the 2022–23 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study
  • +36
  • Marine Maurel,
  • Francisco Pozo,
  • Gloria Pérez-Gimeno,
  • Silke Buda,
  • Noémie Sève,
  • Beatrix Oroszi,
  • Mariette Hooiveld,
  • Verónica Gómez,
  • Lisa Domegan,
  • Iván Martínez-Baz,
  • Maja Ilić,
  • AnnaSara Carnahan,
  • Maria Elena Mihai,
  • Ana Martinez,
  • Luise Goerlitz,
  • Vincent ENOUF,
  • Judit Krisztina Horvath,
  • Frederika Dijkstra,
  • Ana Paula Rodrigues,
  • Charlene Bennett,
  • Camino Trobajo-Sanmartín,
  • Ivan Mlinarić,
  • Neus Latorre-Margalef,
  • Alina Ivanciuc,
  • Aurora Lopez,
  • Ralf Dürrwald,
  • Alessandra Falchi,
  • Gergő Túri,
  • Adam Meijer,
  • Aryse Melo,
  • Joan O'Donnell,
  • Jesus Castilla,
  • Vesna Višekruna Vučina,
  • Tove Samuelsson Hagey,
  • Mihaela Lazar,
  • Marlena Kaczmarek,
  • Sabrina Bacci,
  • Esther Kissling,
  • VEBIS study team
Marine Maurel
Epiconcept SAS

Corresponding Author:m.maurel@epiconcept.fr

Author Profile
Francisco Pozo
Carlos III Health Institute
Author Profile
Gloria Pérez-Gimeno
Carlos III Health Institute
Author Profile
Silke Buda
Robert Koch Institut
Author Profile
Noémie Sève
iPLESP
Author Profile
Beatrix Oroszi
Semmelweis University
Author Profile
Mariette Hooiveld
Netherlands institute of health services research (NIVEL)
Author Profile
Verónica Gómez
Instituto Nacional de Saúde Dr. Ricardo Jorge
Author Profile
Lisa Domegan
Health Service Executive-Health Protection Surveillance Centre
Author Profile
Iván Martínez-Baz
Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP
Author Profile
Maja Ilić
Croatian Institute of Public Health
Author Profile
AnnaSara Carnahan
Public Health Agency of Sweden
Author Profile
Maria Elena Mihai
"Cantacuzino” National Military Medical Institute for Research and Development
Author Profile
Ana Martinez
Agencia de Salud Pública de Catalunya
Author Profile
Luise Goerlitz
Robert Koch Institut
Author Profile
Vincent ENOUF
Institut Pasteur
Author Profile
Judit Krisztina Horvath
Semmelweis University
Author Profile
Frederika Dijkstra
National Institute for Public Health and the Environment (RIVM)
Author Profile
Ana Paula Rodrigues
Instituto Nacional de Saúde Dr. Ricardo Jorge
Author Profile
Charlene Bennett
University College Dublin
Author Profile
Camino Trobajo-Sanmartín
Complejo Hospitalario de Navarra
Author Profile
Ivan Mlinarić
Croatian Institute of Public Health
Author Profile
Neus Latorre-Margalef
Public Health Agency of Sweden
Author Profile
Alina Ivanciuc
Cantacuzino Military-Medical Research-Development National Institute
Author Profile
Aurora Lopez
Subdirección General de Epidemiologia y Vigilancia de la Salud
Author Profile
Ralf Dürrwald
Robert Koch Institut
Author Profile
Alessandra Falchi
Université de Corse-Inserm
Author Profile
Gergő Túri
Semmelweis University
Author Profile
Adam Meijer
National Institute for Public Health and the Environment (RIVM)
Author Profile
Aryse Melo
Instituto Nacional de Saúde Dr. Ricardo Jorge
Author Profile
Joan O'Donnell
Health Service Executive-Health Protection Surveillance Centre
Author Profile
Jesus Castilla
Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP
Author Profile
Vesna Višekruna Vučina
Croatian Institute of Public Health
Author Profile
Tove Samuelsson Hagey
Public Health Agency of Sweden
Author Profile
Mihaela Lazar
"Cantacuzino" National Military Medical Institute for Research and Development
Author Profile
Marlena Kaczmarek
European Centre for Disease Prevention and Control
Author Profile
Sabrina Bacci
European Centre for Disease Prevention and Control
Author Profile
Esther Kissling
Epiconcept SAS
Author Profile
VEBIS study team
Epiconcept SAS
Author Profile

Abstract

Influenza A(H3N2) viruses dominated early in the 2022–23 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study. Primary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, influenza (sub)type and clade, by age group, by influenza vaccine target group and by time since vaccination, using logistic regression. We included 38,058 patients, of which 3,786 were influenza A(H3N2), 1,548 influenza A(H1N1)pdm09 and 3,275 influenza B cases. Against influenza A(H3N2), VE was 36% (95%CI: 25–45) among all ages, ranged between 30% and 52% by age group and target group. VE against influenza A(H3N2) clade 2b was 38% (95% CI: 25–49). Overall, VE against influenza A(H1N1)pdm09 was 46% (95%CI: 35–56) and ranged between 29% and 59% by age group and target group. VE against influenza A(H1N1)pdm09 clade 5a.2a was 56% (95% CI: 46–65) and 79% (95% CI: 64–88) against clade 5a.2a.1. VE against influenza B was 76% (95%CI: 70–81), overall; 84%, 72% and 71% among 0–14-year-olds 15–64-year-olds and those in the influenza vaccination target group, respectively. VE against influenza B with a position 197-mutation of the hemagglutinin (HA) gene was 79% (95% CI: 73–85) and 90% (95% CI: 85–94) without this mutation. The 2022–23 end-of-season results from the VEBIS network at primary care level showed high VE among children and against influenza B, with lower VE against influenza A(H1N1)pdm09 and A(H3N2).
05 Oct 2023Submitted to Influenza and other respiratory viruses
10 Oct 2023Submission Checks Completed
10 Oct 2023Assigned to Editor
28 Oct 2023Reviewer(s) Assigned
12 Nov 2023Review(s) Completed, Editorial Evaluation Pending
14 Nov 2023Editorial Decision: Revise Minor